Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Cantor Fitzgerald
Fuji
Teva
Novartis
Fish and Richardson
Queensland Health
Harvard Business School
Merck

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204371

« Back to Dashboard

NDA 204371 describes GRISEOFULVIN, ULTRAMICROSIZE, which is a drug marketed by Impax Labs Inc and is included in one NDA. It is available from two suppliers. Additional details are available on the GRISEOFULVIN, ULTRAMICROSIZE profile page.

The generic ingredient in GRISEOFULVIN, ULTRAMICROSIZE is griseofulvin, ultramicrosize. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the griseofulvin, ultramicrosize profile page.
Summary for 204371
Tradename:GRISEOFULVIN, ULTRAMICROSIZE
Applicant:Impax Labs Inc
Ingredient:griseofulvin, ultramicrosize
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 204371
Suppliers and Packaging for NDA: 204371
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 204371 ANDA RiconPharma LLC. 51125-005 51125-005-08 500 TABLET, COATED in 1 BOTTLE, PLASTIC (51125-005-08)
GRISEOFULVIN, ULTRAMICROSIZE griseofulvin, ultramicrosize TABLET;ORAL 204371 ANDA RiconPharma LLC. 51125-005 51125-005-06 100 TABLET, COATED in 1 BOTTLE, PLASTIC (51125-005-06)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength125MG
Approval Date:Jan 9, 2014TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength250MG
Approval Date:Jan 9, 2014TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Boehringer Ingelheim
Farmers Insurance
Dow
Healthtrust
Colorcon
Cantor Fitzgerald
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot